These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24075095)

  • 21. Acid-base profile and predictors of metabolic acidosis in patients undergoing peritoneal dialysis with lactate- and bicarbonate-buffered peritoneal dialysis solutions.
    Fourtounas C; Savidaki E; Roumelioti M; Dousdampanis P; Hardalias A; Kalliakmani P; Papachristou E; Drakopoulos A; Goumenos DS; Vlachojannis JG
    Adv Perit Dial; 2006; 22():187-91. PubMed ID: 16983967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
    Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
    Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic acidosis in peritoneal dialysis patients: the role of residual renal function.
    Tian XK; Shan YS; Zhe XW; Cheng LT; Wang T
    Blood Purif; 2005; 23(6):459-65. PubMed ID: 16244471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study.
    Lai B; Cervelli MJ
    Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sevelamer carbonate. No better than sevelamer hydrochloride.
    Prescrire Int; 2010 Jun; 19(107):104-5. PubMed ID: 20738030
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].
    Taniguchi K; Kakuta H; Tomura Y; Kaku S; Uchida W
    Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):333-7. PubMed ID: 23749074
    [No Abstract]   [Full Text] [Related]  

  • 31. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy.
    Akatsuka T; Mochizuki T; Koike T
    Ther Apher Dial; 2008 Jun; 12(3):216-25. PubMed ID: 18503699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Images of the Month: Gastric Pneumatosis Due to Sevelamer-Mediated Necrosis.
    Amer S; Nguyen C; DePetris G
    Am J Gastroenterol; 2015 Jun; 110(6):799. PubMed ID: 26052763
    [No Abstract]   [Full Text] [Related]  

  • 36. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of sevelamer hydrochloride on bone in experimental uremic rats.
    Kuwahara M; Inoshita S; Terada Y; Sasaki S
    Ther Apher Dial; 2009 Feb; 13(1):42-8. PubMed ID: 19379169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sevelamer reduces the efficacy of many other drugs.
    Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.